title: Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
abstract: CONCLUSIONS
  Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis.
  
  
  BACKGROUND
  Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate.
  
  
  METHODS
  A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated.
  
  
  RESULTS
  Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST(R), was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups.
  
  
  CONCLUSIONS
  In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women.
authors.affiliation: Faculty Laennec, Claude Bernard University, Rue G Paradin, 69437, Lyon Cedex 03, France. pierre.meunier@sante.univ-lyon1.fr
authors.forename: P J
authors.initials: PJ
authors.lastname: Meunier
authors.forename: C
authors.initials: C
authors.lastname: Roux
authors.forename: S
authors.initials: S
authors.lastname: Ortolani
authors.forename: M
authors.initials: M
authors.lastname: Diaz-Curiel
authors.forename: J
authors.initials: J
authors.lastname: Compston
authors.forename: P
authors.initials: P
authors.lastname: Marquis
authors.forename: C
authors.initials: C
authors.lastname: Cormier
authors.forename: G
authors.initials: G
authors.lastname: Isaia
authors.forename: J
authors.initials: J
authors.lastname: Badurski
authors.forename: J D
authors.initials: JD
authors.lastname: Wark
authors.forename: J
authors.initials: J
authors.lastname: Collette
authors.forename: J Y
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods; D000368:Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005272:Femur Neck / Q000503:physiopathology; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D058866:Osteoporotic Fractures / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D011788:Quality of Life; D016103:Spinal Fractures / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate